Malcolm Stevens elected as FRS

We would all like to congratulate our Emeritus Professor Malcolm Stevens OBE FRS, on his election as a Fellow of the Royal Society.  Our Head of School, Professor Saul Tendler, says "This is a huge achievement and splendid recognition of  Malcolm's research".

Professor Malcolm Stevens is well-known for his invention of several small nitrogen-based heterocycles for the treatment of cancer. He is the inventor of 'temozolomide' which is active against brain tumours and is licensed by Cancer Research Technologies to Schering Plough Corporation.  Temozolomide achieved sales of over 1 billion dollars in 2008.   The antitumoral benzothiazole known as 'Phortress' was also synthesised in Stevens' laboratory and is currently in Phase 1 clinical trials. 

Professor Malcom Stevens is also chief  scientific officer for a small chemotec company, Pharminox, which is based in Biocity, Nottingham.